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Background and Objectives. The relation between cardiac 
mortxdity and anttarrhytbmir drug administration has no, been 
C&y determined. This r&tion wan anal@ in 1,330 patients 
enmlted in the Stroke Prevention in Atrial Fibrillation Study. a 
randomized clinical trial comparing wariarin, aspirin and placebo 
for the prwention 01 irhemic stroke or systemic emholism in 
patients with nonvalwdar atrtal fibrillation. 
Melhods. Patients who received antiarrhytbmic drug therapy 
hr atrinl6britkdion in this study were compared with patienti not 
receiving pnliarrbythmic agents. The retattvr risk of cardiac 
mortality, imtuding arrhylhmh death, in patients receiving an- 
tinrrbyibmic drug therapy was determined and adjusted for other 
cardiac r&k factors. 
the relative rirh oiarrhythmic death in the treazrd group was 3.7 
Ip = 0.01. 95% Cl 1.3 to 10.4). FUitnLi i;itbw, a biitiw of 
c&ulive heart failure bad no bxreased risk of cardiac mor&ity 
(relative risk 0.70,95% CI 0.2to3.tlduringultiarrb~hmicdrug 
therapy. 
Rcsulrs. In patients receiving nutiarrhytboic drug therapy, 
cardiac mortality was increased 2.5.fdd tp = 6.0+6. 95% cc& 
dense intrrwd [CIj 1.3 104.9) and arrhylhmic death was inmssed 
2.6.bld (p = 0.02, 95% C! 1.2 to 5.6). Among prtie6& xitb 2 
history oi congestive heart iailure, those given aatiarrhylhmic 
mediitionr hada r&live riskofcardiac deathti4.7 (p < 0.001, 
95?6 Cl 1.9 to 11.6) compared with that ofpalteats cat u) Iwaled; 
U,er excluion OE 23 patienti with docomtn,Pd vontrtcutar 
arrhvthmbx and adiu&neot for otkr variables oredtcttw of 
cardLc death. patier& r~iuinpantiarrhythmtcdru~~rreno! at
incre~ed rirk ofcardipe d&h *r arrbythmk death. Nowever, in 
pa,ien,s i,h a h&tow of hear, ftipilu~p who receiwd antiarrbvtb- 
.mic drug therapy, th; retatiss r&k ofcardiac death wan 3.3 ,i = 
0.05.95?& C, 0.99 to 11.1) and that ofarrhytbmtc death was 5.8 
lp = 0.069.95~ Cl 1.5,~21.7Icompa,ed with thertsk in psttents 
no, taking antiarrh@mic medicafiom. 
Conr,‘urionr. Mthcwb nnliarrhvhmt dme theraw lyss not 
randomly dttermbed in”ttdstriat, Ii data ro& iti.; patients 
riib 3,r* .st!,P.:$o 3xdlldstui) ofcwgertiiebwtfail”~~, LbE 
risk of such tkrapy may auhudgh Ike potential baeti, of 
maintaining skms rhythm. 
1J Am Coil Cardiol1992;20:527-32) 
Antiarrhytbmic medications arc commonly given ,O patients 
with atrial fibrillation to restore or maintain sinus rhythm, but 
the balance between risk and benefit of such therapy is under- 
going reasressment. A mela-analysis of six randomized. con- 
trolled hi& incorporating 80F1 patien!s with chronic atrial 
fibrillation ,I) evnb~~ted +idinr far m~in:on~nr~ nf sinw 
rhythm after cardioversion. Although quinidine was mve ef- 
fecrix than no antiarrhythmic therapy in preventing the recur- 
reocc of atnal fibrillation. the risk of death was approximately 
threefold greafer among dmg-treated patients (p : 0.05). a 
conclusion based on only I5 deaths. Dara from a randomized 
trial of patients with ventricular ectopic activity after myocar- 
nism of death among partici&ntr in these studies is specula- 
tive. but a pmarrhythmic drug effect is one consideration (4). 
Prompted by these repons of rncreased mortality atlrib- 
uted to wriarrhythmic dmp. theraov. we examined tbc r&a- 
tion between cardiac m&ali,y -and antiarrhythmic drug 
!h*nnv in the Stroke Prevention in Atrial Fibrillation Studv. 
1 .*‘..a ,..n .c .,,il .,,,., .._ obserxd cxcx cxdix riwii&ig io pa:& 
treated with antiarrhythmic drugs. This report describes the 
ure of antiarrhythmic drugs in patients with uonval~~lar 
atrial fibrillation, the magnituJe of increased morWity asso- 
ciated with anliarrhythmic drug therapy, and the clinical 
features of patients treated with axtrarrhythmic drugs at risk 
for cardiac mortality. 
M&IO& 
Design of the Stroke Prevention in Al&l Fihrillstion 
Study. The main objective ofthe Stroke Prevention in Atrial 
Fibrillation Study was to define the et5.z~ and toxicity of 
warfarin and aspirin, administered separalely, for prevention 
of ischemic stroke and systemic embolism in patiertts with 
constant or intermittent nonvalvular atrial fibrillation. The 
design, subjects and definition of clinical variables of this 
randomized clinical trial have been previously described in 
detail (5,6). Between June 1987 and November 1989, 1,330 
patients were enrolled at I5 clinical centers in the United 
States. On enlry into the study, historical features including 
cardiovascular risk factors and previous cardiac events were 
recorded. A physical examinntion with an evaluation of 
functional status was performed. Medications admin&red 
for cardiovascular disorders were noted. Blood chemistry 
and bematologic profiles. 124ead electrocardiograms and 
M-mode and two-dimensional echocardiograms were per- 
fortned. Atrial fibrillation was characterized by its duratic,n. 
intermittency and presumed etiology. Patients were followed 
up at 3.month intervals to record concurrent medications. 
detect ischemic stroke and systemic emboli and identify 
complications of drug therapy. 
The decision lo administer antiarrhythmic drug therapy 
was made hy the p&m’s personal physician and was not 
randomly assigned. Patients receiving antiarrhythmic drug 
therapy were identified at entry into the study or during 
routine fotlow-up and form the basis of this report. Patients 
receiving antiarrbytbmic drug therapy at the time of death 
but not recorded as receiving these drugs at the time of last 
follow-up visit (n = 5) are no: included in our analysis to 
avoid potential bias. 
Classification of cause of death, Medical records pertain- 
ing to all deaths were initially reviewed by members of an 
Events Verification Committee who had no knowledge of 
antithrombotic treatment assignment and who classified aI1 
deaths as vascular or nonvascular. A second group of invest+ 
gators (cardiologists), who had no knowledge ofantiarrhythmic 
therapy status, made a subsequent review toclassify the cause 
of death as cardiac or noncardiac. Cardiac deaths were sub- 
classified as arrbytbmic or nonarrhythmic by using standards 
similar to those set forth by the Cardiac Arrhythmia Suppres- 
sionTrial (CAST) investigators (3). Death wasconsidered tobe 
due to an arrhythmia in the following circumstances: 1) wit- 
nessed and instanraneous, without new acceletaIing sytnp- 
tams; 2) witnessed and prezded by chest pain, overt myocar- 
dial infarction, or mhythmic symptoms (syncope OT near 
syncop); or 3) unwitneszd bd without evidence of another 
WY0Y. YCYLII> Y.CCWC” ^n**nn nnn*Ln --“..,w by shock or severe heart faiture were 
considered cardiac related but not due to an arrhythmia even if 
the terminal event was Al arr!hythmia. 
Statical q ethadolngy. The analysis proceeded in a stcp- 
wise fashion to determine the independent contribution of 
patient subgroups at increased risk when exposed to antiar- 
rhythmic drug therapy. Cardiac mortality ii? patients during 
antiarrhythmic drug therapy was analyzed. This survival 
analysis considered all exposure to antiarrbytbmic drugs 
whether present at entry or initiated durinp follow-up to 
estimnP the risk associated with antiarrhythmic drug tber- 
spy. Second. I6 variables cunsidersd poienii; independent 
risk factors for cardiac death were prospectively selected, 
These variables were characterized at study entry and 
included age; gender; cument smoking; history of hyperten- 
sion; history ofdiabetes; definite history of angina; history of 
myocardial infarction; definite history of congestive heart 
failure (defined as orthopnea, dyspnea or edema responding 
to diuretic therapy; third sound gallop and rales; X-ray 
evidence of cardiomegaly or vascular distribution: and left 
ventricular filling pressun >1S mm HgJ; New York Heart 
Association functional class II or 111 (patients in class IV 
were excluded fmm the stud)); recent heart failure (within 
100 days); moderate to sever: left ventricular wall motion 
abnormality by ecbocardiagralbhy: assignment to aspirin or 
warfarin, and the use of digitalis. diuretics, beta-adrenergic 
blocking agents or calcium channel blockers. A multivariate 
analysis was performed by using the proportional hazards 
failure time model of Cox. The adjusted risk (instantaneous 
hazard ratio) of cardiac death independently associated with 
anriarrhyrbmic drug therapy was estimated by using covari- 
ables significantly associated with cardiac death. Third, we 
examined the interaction between an&rhythmic drug ther- 
apy and the other predictors of cardiac death to identify 
subgroups of patients in whom the risk of antiarrhythmic 
drugs was especially great. Finally, we assessed the inde- 
pendent contribution of antiarrhythmic drug therapy to 
cardiac mortality in these high risk subgroups after adjusting 
for the I6 variables described. 
Patim ts receiving anfiarrhyfhmic drugr for ventricular 
arrhyhdas. Specific antiarrhythmic drubs included qtini- 
dine (n = 127), procaittamide (n = 57), disopyramide (n = 
IS), llecainide (n = 34), ettcidnide (n = 20) and amiodarone 
(n = 7). Patients may have been taking more !han one agent 
during follow-up. The presence of ventricular arrhythmias 
was not assessed at entry into the study. However, medical 
records of all patients receiving antianhythmic drugs were 
reviewed to identify additional indications for theqy. 
These indications included symptomatic ventricular prema- 
ture complexes and nonsustained and sustained ventricular 
tachycardia. Twenty-three patients were identified who H- 
ceived antiarrhytbmic drugs for chronic ventricular anfiytb- 
miss and atria1 fibrillation. An analysis similar to tbzt de- 
scribed for the entire population was then rep&cd after 
exclusion of patients rcctiving mti~;hythmic dnts for 
ventricular arrhythmias. 
Botisticol fests. Comparisons of baseline characteristics 
were made hy !he CL-square statistic or I test for categorical 
and continuous variables resmtivelv. Mortalitv rates were 
antiarrhythmic drug: therapy to cardiac death in the entire estimated using the Kaplan-‘Meier method (7).~CnnCde~e 
Stroke Prevention in Atrial Fibrillation Study cohort and in intervals were calcnlated at the 95% level. Multivariate 
at~lyses to estimate the association between covariates and tachycardia or ventriculer fibrillation (n = 8). Total exposure 
outcome were xfomted usin,: the proportional hazards to antiarrhythrmc drug therapy was 201 patient-years. Pa- 
failure time model of Cox (8). A.dia:rhythmic drug thenpy tients treated with antiarrhythmic agents were younger, had 
status was assessed at each scheduled follow-up visit and a lesser prevalence of hypertension and a greater prevaience 
was analyzed as a covariate varying with time. of a history of ntyocardial infarctian and of intemtittent atria: 
fibrillation and recent cardiavenion and used diuretics more 
ReSUlt.9 
frequentI:’ than did pativts nor giver! antirurhythmic agents 
(Table I). 
Of the 1,330 randomized patients. 244 06%) received During a mean follow-up interval of 1.3 yeers, 89 deaths 
antiarrhythmic medica!iarts either 8t the time of enrollment ccczred in the study cohort. Fc*y Cve dez!hs wcrc classi- 
!:: = IE9) or after enrollment (n = 55). In most cases (91%). tied as noncardiac and 44 as cardiac in origin. Thirty-two 
tmtiarrbythmic drugs were prescribed for the prevention of cardiac dearhs were considered to be due to an arrhylhmia, 
symptomatic atriai fibtillatian. Twenty-three patients (%) including 19 unwitnessed eaths. 7 witnessed deaths without 
also received these agents for ventricuhr arrhythmias in- preceding symptoms and 6 deaths preceded by chest pain or 
&ding premature ventricular beats (18 = IO). nonsustained arrhythmic symptoms; I? cardiac deaibs *err not r&ted to 
ventricular txhycardia (n = 5). and sustained ventricular an arrhythmia. 
Cardiac and arrhythmic mortali!y in the entire cohort. 
Cardiac mortality among patients receiving antiarrhythmic 
drug therapy was 5%ipaticnt-yenr; among patients not taking 
antiarrhythmic drugs. cardiac mortality was 2.2%/paticnr- 
year. The relative risk of cardiac death for patients receiving 
antiarrhythmic drug therapy was 2.5 lp = O.Cil6.95% confi- 
dence interval [Cl] I.3 to 4.9) compared with the risk of 
patients not treated with these agents. Considering o:rly 
arhythmic deaths, the relative risk during antiarrhythmic 
drug use was 2.6 (p = 0.02, 95% Cl I.2 to 5.6). After 
adjustment for the prospectively selected predictors of car- 
diac death, the relative risk of cardiac death for patients 
receiving antiarrhythmic agents was 2.7 (p = 0.007.95% Cl 
1.3 to 5.5) and the rclativc risk of anhythmic death was 2.3 
(p = 0.04,95% CI 1.0 to 5.1) compared with that of patients 
not receiving antiarrhjithmic agents. 
Mortality in patients with a history of heart failure. The 
increased relative risk of cardiac and arrhythmic death 
during antiarrhythmic drug therapy was especially noted in 
patients with a historv of hear! failure. In these patients. the 
relative risk of cardiac death during antiarrhyttnmic therapy 
was 4.1 ID CC O.M)I. 95% Cl 1.9 to 11.6). Restrictine the 
analysts ii arrhylhmic deaths. the relative risk was 3.7(p = 
0.01,95% Cl I .3 to 10.41. The increased relative risk of death 
in patients with a htstorv of congestive heart failure who 
xc&d antiarrhythmic drug therapy was constant hrough- 
out the 1st year of ahservation (Fig. I). There was no 
increased risk of cardiac death during antiarrhythmic ther- 
apy in patients without B dctinite b&tory of heart failure 
Irelative risk 0.70.9SW Cl = 0.2 to 3. I). 
Mortality in patients without ventricular arrhythmias. 
After exclusion of the 23 patients with ventricular arrhy”,. 
miss, the relative risk of cardiac death in patients rccciving 
antiarrhythmic drug therapy WBE only I.6 lp = 0.24) com- 
pared with the risk of those not taking these drugs. For 
arrhythmic deaths the relative risk in patients receivb@ 
antiarrhythmic drug therapy compared with the risk in 
tntientr not takiw these drum was onlv 2.0 (n = 0.13). Even 
gftcr adjustment ior other predictors bf car&c death, pa- 
tients receivine antianhvthmic drues had a relative risk of 
1.8 for cardiac death (p = 0.20)“and a relative risk of 
arrhvthmic death of 2. I to = 0. II) cornoared with tbc risk in 
those not receiving anti&rhythmic drug therapy. However, 
among patients with a history of heart failure who received 
antisrrh;jthmic drugs. the relative risk of cardiac death was 
2.9 (p = 0.04. 95% Cl I.1 to 8.2) and the relative risk of 
arrhythmic death was 4.1 (p = 0.02. 95% Cl I.2 to 13.5) 
compared with the risk of patients not receiving these drugs. 
After adjustment for the prospectively selected predictors of 
cardiac death, these patients had a relative risk of cardiac 
deathof3.3(p =0.05,9S%CI0.99toIl.l)andarclativerisk 
of arrhythmic death of 5.8 (p = 0.W. 95% CI I.5 to 21.7) 
<:ompamd with the rink of patients not taking antiarrhythmic 
,drugs (Table 2). 
A comparison of tt.c bas+ne clinical and echocardio- 
graphic features of the 239 patients without ventricular 
arrhythmias and with a history of heart failure showed that 
patients taking a&u-rhythmic drugs were younger. and had 
a greater prevalence of intemtittent atrizl fibrillation and 
angina than did patients not takinp. antiarrhythmic drugs 
(Table 3). 
This study demonstrates increased cardiac mortality in 
Dalients with atrial fibrillation treated with antialrhvtn,nic 
mic drug therapy. 
Causes of lucreawl mortality. The mechanism of in- 
creased cardiac mottality with antiarrhythmie drug therapy 
in thin study remains spectdative. A drug-induced ventricu- 
lar mhythmia is a psible explanation for these events. 





due to an arrhylhmia but >S@% were unwitnessed, raising 
uncertainties about the cause of death. The relatively small 
number of cardiac deaths prevents us !rom commenting on 
individual anttarrhythmic drugs and their assaiation with 
cardiac mortality. 
Antiarhythmic agents may provakz ventricular arrhyth- 
miss in patients treated for atrial or ventricvlar arrhythmias 
(9-12: aad have been implicated as ace?lse of out-of-hospital 
cardiac arrest (9). Quinidine. a class IA agent and the most 
L.onm~mdy presrihed anharrhythmic drug in the study (ti- 
hort, has a-reported prowrhythmic rate of 15% in patients 
..^“.“A rn? v”,,ir,,,.r “rL...L-:.. <a,, TL:. ^“-I.. -----. . ..I.... ._. ._...,.-_._ .” . ...” . . . . *“., ,._,. . . . . . . . ..a*. I.“‘” 
rhythmic effect usually occws within 3 to 4 days (14) and 
often occurs in patients with left ventricuiar dysfuncrion 
(12). In most of OUT patients, a&rhythmic drugs were 
initiated before study entry. Consequently, an early proar- 
rhythmic e&t would not have been observed. Our data 
suggest that the risk of cardiac death in patients with a 
history of hean failure who receive antiarrhythmic drug 
therapy continues throoghou! the period ofdrug use. This i> 
consi~en! whh a late proarrhythmlc effect. 
Our analysis way based on otwrvatiom of a large cohort 
representative of a broad population of patients with non- 
valvular atrial fibrillation. Treatment with antiarrhythmic 
agents was not randomly allocated. Hence other cardiovas- 
cular variables associated with the use of antiarrhvthmic 
drugs may have accounted for the increased mortaliiy rate. 
Vcmricular arrhythmias may bavc been one such variable. 
Another plausible basis for excess deaths is that patients 
with more severe congestive heart failure may have been 
selected for ant&rhythmic drug treatment. The similarity of 
functional class%cation at the time of enmllment and corn. 
parable echocardiographic measurements of left ventricular 
size and function in patients who were and were not receiv- 
ing antmrrhythmic drugs suggest that such a selection bia 
does not a.ccount entirely for the observed difference in 
mortality. The posGbility that certain patients experienced 
hemodynamic deterioration during the study and received 
antiarrhvthmic drue theraov which contributed to increased 
mortalif; cannot be exclubkd by our data. 
Clarification of the rla:ios of antiarrhythmic drug ther- 
apy was not a primary objective of the Stroke Prevention in 
Atrial Fibrillation Study. However, this analvsis was per- 
formed specifically seeking an association beiween a&r- 
rhythmic drug therapy and an increase in increased cardiac 
mortality, strengthening its validity. We recognize that this 
type of analysis cannot replace a prospective, randomized 
trial but at present this type of trial has not been organized. 
Conclusions. Antiarrhyrhmic drugs are frequently pre- 
scribed in patients with congestive heart failure to preserve 
atrial transport and improve cardiac output. A cautious 
interpretation of the available data favors the addition of 
antiarrbythmic drugs in patients with atrial fibrillation who 
bave a biarory of heart failure only tn circumstances when 
symptoms are severe and not amenable to other formr of 
therapy. 
